首页> 外文会议>Society for Biomaterials Annual Meeting and Exposition >Avidity-Driven Targeting of a Novel Biohybrid Nanoscale Carrier Engineered for High Therapeutic Payload and Extended Release of Anticancer Drugs to Treat Small Cell Lung Cancer
【24h】

Avidity-Driven Targeting of a Novel Biohybrid Nanoscale Carrier Engineered for High Therapeutic Payload and Extended Release of Anticancer Drugs to Treat Small Cell Lung Cancer

机译:厌恶的靶向靶向高治疗有效载荷和抗癌药物的高治疗有效载荷和延长释放以治疗小细胞肺癌的靶向靶向

获取原文

摘要

The proposed research involves the first avidity-driven high payload programmable nanocarrier that can be administered either intravenously or intratracheally. Due to the design of the nanocarrier we are able to highly regulate the interactions of the drug to the binding sites and unwanted interactions between the cell-specific aptamer and the drug-binding sequences. In addition, we have been able to optimize the amount of anchor that can bind to the AuNp by adjusting the salt and DNA concentrations. The release rate and quantity of drug can be controlled and manipulated by "mutating" the base pairing in the drug-binding region and by changing the length of the sequence. Preliminary data suggests that our carrier will be able to deliver more drugs per particle than any other AuNp platform known to our knowledge. On going work includes a full analysis and testing of drug efficacy for removal of SCLC from orthotopic nude mouse models using each SCLC-specific aptamer from Chen et al. to determine the most effective aptamer.
机译:所提出的研究涉及第一个可亲密的高效载荷可编程纳米载体,其可以静脉内或肿瘤内施用。由于纳米载体的设计,我们能够高度调节药物与结合位点的相互作用,并且在细胞特异性适体和药物结合序列之间的不希望的相互作用。此外,我们能够通过调节盐和DNA浓度来优化可以与AUNP结合的锚的量。通过“突变”在药物结合区域中的基础配对并通过改变序列的长度,可以控制和操纵药物的释放速率和量。初步数据表明,我们的运营商将能够每粒子提供更多的药物,而不是我们知识所知的任何其他AUNP平台。在去工作中,使用来自Chen等人的每个SCLC特异性适体从原位裸鼠模型中除去SCLC的药物疗效的完全分析和测试。确定最有效的Aptamer。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号